– Stephen Fisher, managing director –
APAC, BioTek, US
BioTek, a US-based company focusing on hybrid microplate
detection technology, has released its new product, the Synergy H1
Hybrid Multi-Mode Microplate Reader, a low-cost hybrid technology
catering to the academic research community. According to the
company, this latest addition to its patent-pending product line
expands the performance, versatility and flexibility offered by hybrid
technology. With this launch, the company will look at grabbing 20
percent market share in India. Stephen Fisher, managing director –
APAC, BioTek, speaks exclusively with BioSpectrum. Excerpts from the
interview.
Q
What are the unique features of Synergy H1 Hybrid Multi-Mode Microplate
Reader?
The product was launched simultaneously across the world and our
distributors in each region will take it forward from there. With
this launch, we will gradually expand our business into the hybrid
technology market and the advantage of this product is that it offers
our life sciences customers, the flexibility, quality outputs,
performance and above all value for money. Usually, multi-mode
microplate readers are expensive and are affordable only to
pharmaceutical, CRO and drug discovery companies. Academic institutions
and universities that are into basic research cannot afford such
high-cost machines.
Synergy H1 Hybrid Multi-Mode Microplate Reader is a cost-effective
technology as it is 30 percent less expensive than the usual
high-end multi-mode micro plate reader (whose price range is
anywhere between
19.67
lakh-
23.42
lakh ($42,000-$50,000). This product is available at a price range
between
13.11
lakh-
16.39
lakh ($28,000-$35,000). So unlike our Synergy H4 technology which has a
lot of luxury features, we have designed the Synergy H1
technology to cater to those into basic research, mainly molecular
biology research.
Q
What is the targeted market
share for Synergy H1 in India?
We have launched this product worldwide at one go and not in phases, as
usually adopted by companies, to first test the product in a market and
mitigate the risk. We are confident about this product. In India,
we have launched it to our distributors who, at the moment, are
training their sales force about this product. In India, we are
looking at grabbing a 20 percent market share in this product segment,
over the next 18 months. We have designed this product in tune
with the Indian market, rather than the US and Western markets.
Q
What is the company’s overall
strategy for India?
In the next five years, we are looking at a year-on-year growth rate of
15 percent. We will grow quickly especially with the launch of the
Synergy H1 Hybrid Multi-Mode Microplate Reader. Over the past three
years, we have been doing extremely well in India. We will be investing
heavily in people and support services, a lot into demonstration
equipments. These investments will double our business in India in
coming years. We will also look at a 50-60 percent increase in capacity
in India. We are here to stay in India.
Q
What are the recent achievements of BioTek in the Asia Pacific region?
In the APAC region, we have seen a 30 percent increase in revenues over
2009. A split up of the regions shows that in India we have grown by 15
percent, South Korea has shown tremendous growth of over 30 percent
increase, China (35 percent), Australia (over 30 percent) growth.
—Nayantara Som in Mumbai